However, patients with mutations in the phosphatidylinositol 3-kinase (PI3K) pathway have shown poor response to irreversible EGFR-TKIs because these mutations activate signals that continue to promote cancer cell growth, even when EGFR is blocked [6,7]. This evidence concerns the gene EGFR and cancer.